CDEK
← All drugs Report issue

methamphetamine

Trade name: desoxyn

Small moleculeapproved

Approved

Dec 31, 1943

Methamphetamine is a potent central nervous system (CNS) stimulant that is mainly used as a recreational or performance-enhancing drug and less commonly as a second-line treatment for attention deficit hyperactivity disorder (ADHD). It has also been researched as a potential treatment for traumatic brain injury. Methamphetamine was discovered in 1893 and exists as two enantiomers: levo-methamphetamine and dextro-methamphetamine. Methamphetamine properly refers to a specific chemical substance, the racemic free base, which is an equal mixture of levomethamphetamine and dextromethamphetamine in their pure amine forms, but the hydrochloride salt, commonly called crystal meth, is widely used. Methamphetamine is rarely prescribed over concerns involving its potential for recreational use as an aphrodisiac and euphoriant, among other concerns, as well as the availability of safer substitute drugs with comparable treatment efficacy such as Adderall and Vyvanse. While pharmaceutical formulations of methamphetamine in the United States are labeled as methamphetamine hydrochloride, they contain dextromethamphetamine as the active ingredient. Dextromethamphetamine is a stronger CNS stimulant than levomethamphetamine. — Wikipedia

Clinical trial activity

21 trials · 14 clinical orgs · 11 marketing orgs

Phase 1
13
Phase 2
3
Phase 3
0
Phase 4
3

Earliest trial started Oct 1, 2008 (NCT00829634)

Timeline

1940s

  1. Dec 31, 1943

    Earliest FDA Approval

  2. Dec 31, 1943

    Recordati — NDA Secondary Org

  3. Dec 31, 1943

    KEY THERAP — Marketing Organization

  4. Dec 31, 1943

    KEY THERAP — NDA Secondary Org

  5. Dec 31, 1943

    AJENAT PHARMS — Marketing Organization

1970s

  1. Jan 19, 1976

    Rexer Pharma — Marketing Organization

2000s

  1. Feb 25, 2004

    Able Laboratories — Marketing Organization

2010s

  1. Apr 21, 2010

    Mayne Pharma — Marketing Organization

  2. Apr 21, 2010

    Dr. Reddy's Laboratories — Marketing Organization

  3. Jan 1, 2013

    Earliest Phase 1 Sponsor(trial)

  4. Nov 17, 2015

    West-Ward Pharmaceutical — Marketing Organization

  5. Nov 17, 2015

    Hikma — Marketing Organization

  6. Jan 1, 2016

    Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedDec 31, 1943

Chemistry & pharmacology

Loading structure…

SMILES

CN[C@@H](C)Cc1ccccc1
Mol. weight
149.24 g/mol
Lipinski Ro5
Pass
Rule of 3
Yes
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

Black box warning

Sources

Also known as

  • (alphas)-n,alpha-dimethylbenzeneethanamine
  • (alphas)-n,alpha-dimethylbenzeneethanamine
  • d-amphetamine
  • desoxyephedrine hcl
  • desoxyephedrine hcl
  • desoxyn
  • desoxyn
  • desoxyn
  • d-methamphetamine
  • d-methamphetamine
  • d-methamphetamine
  • d-methylamphetamine
  • d-n-methylamphetamine
  • d-n-methylamphetamine
  • d-phenylisopropylmethylamine
  • d-phenylisopropylmethylamine
  • l-desoxyephedrine
  • levmetamfetamine
  • levomethamphetamine
  • l-methamphetamine
  • l-methamphetamine
  • l-methamphetamine
  • l-methylamphetamine
  • metamfetamine
  • metamfetamine
  • metamfetamine
  • metamfetamine
  • métamfétamine
  • métamfétamine
  • metamfetaminum
  • metamfetaminum
  • metanfetamina
  • metanfetamina
  • methampex
  • methampex
  • methamphetamine
  • methamphetamine
  • methamphetamine
  • methamphetamine
  • methamphetamine
  • methamphetamine
  • methamphetamine
  • methamphetamine
  • methamphetamine
  • methamphetamine
  • methamphetamine hcl
  • methamphetamine hcl
  • methamphetamine hcl
  • methamphetamine hydrochloride
  • methamphetamine hydrochloride
  • methamphetamine hydrochloride
  • methamphetamine hydrochloride
  • methamphetamine hydrochloride
  • methamphetaminum
  • methamphetaminum
  • methylamfetamine hydrochloride
  • methylamfetamine hydrochloride
  • methylamphetamine
  • methyl-beta-phenylisopropylamine
  • methyl-beta-phenylisopropylamine
  • methyl-β-phenylisopropylamine
  • methyl-β-phenylisopropylamine
  • (r)-deoxyephedrine
  • (r)-methamphetamine
  • (r)-methylamphetamine
  • (s)-methamphetamine
  • (s)-n,alpha-dimethylbenzeneethanamine
  • (s)-n,alpha-dimethylbenzeneethanamine
  • (+)-(s)-n-alpha-dimethylphenethylamine
  • (+)-(s)-n-alpha-dimethylphenethylamine
  • (s)-n,α-dimethylbenzeneethanamine
  • (s)-n,α-dimethylbenzeneethanamine
  • (+)-(s)-n-α-dimethylphenethylamine
  • (+)-(s)-n-α-dimethylphenethylamine
  • (αs)-n,α-dimethylbenzeneethanamine
  • (αs)-n,α-dimethylbenzeneethanamine

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06989853Early Phase 1 (Phase 1)Aug 25, 2025National Institute on Drug Abuse (NIDA), University of Kentucky
NCT06746831Phase 1Mar 31, 2025University of Wisconsin, U.S. Department of Justice
NCT06721494Phase 2Mar 31, 2025Clear Scientific, Inc., National Institute on Drug Abuse (NIDA)
NCT05783817Phase 2Dec 1, 2023Stanford University
NCT05379959Early Phase 1 (Phase 1)May 11, 2022University of Chicago
NCT05003076Early Phase 1 (Phase 1)Jul 1, 2021University of Chicago
NCT04614584Phase 1Jan 1, 2021City of San Francisco, University of California, Los Angeles
NCT04642820Early Phase 1 (Phase 1)Nov 15, 2020University of Chicago
NCT04178993Phase 1Sep 1, 2019National Institute on Drug Abuse (NIDA), University of Kentucky
NCT03973489Phase 4Aug 16, 2019Department of Veteran Affairs, Oregon Health and Science University
NCT03825536Phase 4Jul 1, 2019National Institute on Drug Abuse (NIDA), University of California, San Francisco
NCT03106571Phase 1May 1, 2017National Institute on Drug Abuse (NIDA), University of California, Los Angeles
NCT03226223Phase 2Sep 15, 2016Columbia University
NCT03790618Phase 1Jun 1, 2016University of Chicago
NCT02383043Early Phase 1 (Phase 1)Feb 1, 2015University of Kentucky
NCT02323048N/AJul 1, 2014University of Chicago
NCT02058966Early Phase 1 (Phase 1)Jun 1, 2014Department of Veteran Affairs, Oregon Health and Science University
NCT01967381Early Phase 1 (Phase 1)Oct 1, 2013National Institute on Drug Abuse (NIDA), University of Kentucky
NCT01843205Phase 1Apr 1, 2013National Institute on Drug Abuse (NIDA), University of Kentucky
NCT01529892Phase 4Feb 7, 2012University of California, San Francisco
Showing 20 of 21 trials
Page 1 / 2

Organizations

Research & Development (14)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Institute on Drug Abuse (NIDA)Government7032013
University of ChicagoAcademic/Hospital5522014
University of KentuckyAcademic/Hospital5512013
University of California, San FranciscoAcademic/Hospital3322008
Department of Veteran AffairsGovernment2022014
Oregon Health and Science UniversityAcademic/Hospital2222014
University of California, Los AngelesAcademic/Hospital2112017
City of San FranciscoGovernment1112021
Clear Scientific, Inc.For profit1112025
Columbia UniversityAcademic/Hospital1112016
National Institutes of Health (NIH)Government1012008
Stanford UniversityAcademic/Hospital1112023
University of WisconsinAcademic/Hospital1112025
U.S. Department of JusticeGovernment1012025
14 organizations
Page 1 / 1

Marketing (13)

OrganizationOrg typeRelationshipDate
AJENAT PHARMSFor profitMKTGDec 31, 1943
AbbottFor profitNDA—
Able LaboratoriesFor profitMKTGFeb 25, 2004
Dr. Reddy's LaboratoriesFor profitMKTGApr 21, 2010
HikmaFor profitMKTGNov 17, 2015
HikmaFor profitSYNNov 17, 2015
KEY THERAPFor profitMKTGDec 31, 1943
KEY THERAPFor profitNDA2Dec 31, 1943
Mayne PharmaFor profitMKTGApr 21, 2010
RecordatiFor profitNDA2Dec 31, 1943
Rexer PharmaFor profitMKTGJan 19, 1976
TevaFor profitMKTG—
West-Ward PharmaceuticalFor profitMKTGNov 17, 2015